Home › NDC Lookup › RxCUI directory › RxCUI 616817

Budesonide 0.25 MG/ML Inhalation Suspension [Pulmicort] — RxCUI 616817

RxNorm drug concept · Semantic branded drug
RxCUI 616817 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI616817
Official nameBudesonide 0.25 MG/ML Inhalation Suspension [Pulmicort]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asPulmicort Respules 0.25 MG/ML Inhalation Suspension; Pulmicort Respules 0.5 MG in 2 ML Inhalation Suspension; Pulmicort Respules 0.5 MG per 2 ML Inhalation Suspension
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)2,817 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Budesonide Nasal Spray: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It temporarily relieves hay fever and other upper respiratory allergy symptoms. That means nasal congestion, runny nose, itchy nose and sneezing.
  • Some symptoms may improve on the first day. It can take up to two weeks of daily use to get the most relief. If you aren't better after two weeks, stop and talk to a doctor.
  • Shake the bottle well, then spray into your nose while sniffing gently. Prime a new bottle first, and again if you haven't used it in two days. Don't spray into your eyes or mouth,...
  • Children 6 to under 12 can use it with an adult supervising. It's not for children under 6. It may slow growth in some children, so check with their doctor if they need it for more...
📖 Read our full Budesonide Nasal Spray guide →

🕸️ Concept Web — How Budesonide 0.25 MG/ML Inhalation Suspension [Pul... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Budesonide 0.25 MG/ML Inhalation Suspension [Pulmicort] RxCUI 616817

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Budesonide 19831
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pulmicort 196487
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Budesonide Inhalation Suspension 2108295
    • Budesonide Inhalant Product 1156070
    • Budesonide Inhalation Suspension [Pulmicort] 2108297
    • Pulmicort Inhalant Product 1183558
    • Inhalation Suspension 2107948
    • Inhalant Product 1151123
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Budesonide 0.25 MG/ML [Pulmicort] SBDC · 616816
  • Budesonide Inhalation Suspension [Pulmicort] SBDF · 2108297
  • Pulmicort Inhalant Product SBDG · 1183558
  • Pulmicort BN · 196487

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 616817 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00186-1988-04 6 POUCH in 1 CARTON (0186-1988-04) / 5 AMPULE in 1 POUCH /... PULMICORT RESPULES AstraZeneca Pharmaceuticals LP 2000-09-08
00186-1989-04 6 POUCH in 1 CARTON (0186-1989-04) / 5 AMPULE in 1 POUCH /... PULMICORT RESPULES AstraZeneca Pharmaceuticals LP 2000-09-08
00186-1990-04 6 POUCH in 1 CARTON (0186-1990-04) / 5 AMPULE in 1 POUCH /... PULMICORT RESPULES AstraZeneca Pharmaceuticals LP 2007-09-17
Observed labelers: AstraZeneca Pharmaceuticals LP (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J7626 Budesonide non-comp unit 3 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.